Intravitreal ranibizumab does not affect retinal vessel size in DME

02/24/2014 | Healio (free registration)

A study in the Journal of Retinal and Vitreous Diseases found that intravitreal administration of ranibizumab did not show significant impact on retinal vessel diameter among diabetic macular edema patients. Researchers also found that reductions in central foveal thickness following ranibizumab treatment were not associated with altered retinal vessel diameter or dilatatory response in patients.

View Full Article in:

Healio (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY